Pancreatic Cancer Research

ResearcherHarold C. Simmons Comprehensive Cancer CenterActive in the last 2 years

Patricio Marcelo Polanco

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1719-1208; OpenAlex author ID A5034674540, A5061447229, A5158637980. Sources: ClinicalTrials.gov.

Their work

Papers
24 (first author 0, last author 9)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
105
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 5 papers · 2024: 3 papers · 2025: 4 papers, 1 trial · 2026: 6 papers

Papers 24

  1. Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy. Co-author DOI 10.1002/jso.70179↗
  2. Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results. Co-author DOI 10.1093/oncolo/oyag416↗
  3. Combined Association of Time to Treatment, Guideline Concordance, and Neighborhood Vulnerability with Localized Colon Cancer, Non-small-cell Lung Cancer, and P… Last author DOI 10.1245/s10434-026-19760-5↗
  4. The PancreaSure Multianalyte Blood Test Performs Well at Distinguishing Early-Stage Pancreatic Ductal Adenocarcinoma from High-Risk Controls: A Retrospective S… Co-author DOI 10.3390/jcm15197355↗
  5. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  6. Irreversible electroporation associated with improved overall survival vs standard of care for stage 3 pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.05.19.26353144↗
  7. Post-operative patterns of failure and outcomes reveal opportunities to optimize treatment of recurrent pancreatic cancer Co-author DOI 10.1101/2025.11.08.25339815↗
  8. Presurgical Ablative Radiation Is Associated with Local Control and Immune Response in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-3582↗
  9. Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: An American Mult… Co-author DOI 10.1245/s10434-025-16916-7↗
  10. Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol32110638↗
  11. Minimally invasive pancreaticoduodenectomy: A favorable approach for frail patients with pancreatic cancer. Last author DOI 10.1016/j.surg.2023.12.022↗
  12. Delta Radiomic Features Predict Resection Margin Status and Overall Survival in Neoadjuvant-Treated Pancreatic Cancer Patients. Co-author DOI 10.1245/s10434-023-14805-5↗
  13. Effectiveness and Safety of Irreversible Electroporation When Used for the Ablation of Stage 3 Pancreatic Adenocarcinoma: Initial Results from the DIRECT Regis… Co-author DOI 10.3390/cancers16233894↗
  14. Factors associated with failure to operate and its impact on survival in early-stage pancreatic cancer. Last author DOI 10.1002/jso.27357↗
  15. Implications of the interaction between travel burden and area deprivation for patients with pancreatic cancer. Last author DOI 10.1016/j.amjsurg.2023.06.013↗
  16. A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising… Co-author DOI 10.1097/sla.0000000000005904↗
  17. Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter? Last author DOI 10.1245/s10434-023-13308-7↗
  18. ASO Author Reflections: Expanding Guideline Concordant Care: The Time for a National Accreditation Program for Pancreatic Cancer is Now. Last author DOI 10.1245/s10434-023-13376-9↗
  19. Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes. Co-author DOI 10.1016/j.ijrobp.2022.07.019↗
  20. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  21. Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States. Last author DOI 10.1245/s10434-019-08096-y↗
  22. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma. Last author DOI 10.6004/jnccn.2018.7068↗
  23. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. Last author DOI 10.1200/jco.2016.68.5081↗
  24. Survival analysis of veteran patients with pancreatic cancer. Co-author DOI 10.1111/1751-2980.12361↗

Trials 1

  1. Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI) Principal investigator NCT06947395↗

Closest collaborators

The 25 strongest of 105 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Herbert J. Zeh · 12 shared papers, 2020–2026 · strength 2.31
  2. Adam Charles Yopp · 9 shared papers, 2017–2025 · strength 1.37
  3. Matthew R. Porembka · 9 shared papers, 2017–2025 · strength 1.35
  4. Gilbert Zvikomborero Murimwa · 5 shared papers, 2023–2026 · strength 1.10
  5. Todd Anthony Aguilera · 5 shared papers, 2022–2026 · strength 0.89
  6. John C. Mansour · 6 shared papers, 2017–2025 · strength 0.81
  7. Sam C. Wang · 6 shared papers, 2017–2024 · strength 0.81
  8. Sean Patrick Cleary · 3 shared papers, 2024–2026 · strength 0.74
  9. Michael D. Kluger · 3 shared papers, 2024–2026 · strength 0.74
  10. Carlos H.F. Chan · 3 shared papers, 2024–2026 · strength 0.74
  11. Rebekah Ruth White · 3 shared papers, 2024–2026 · strength 0.74
  12. Robert C.G. Martin · 3 shared papers, 2024–2026 · strength 0.74
  13. Ahmed M. Elamir · 4 shared papers, 2022–2025 · strength 0.70
  14. Emile Farah · 3 shared papers, 2024–2026 · strength 0.63
  15. Nina Niu Sanford · 3 shared papers, 2022–2025 · strength 0.54
  16. Syed Mohammad Ali Kazmi · 3 shared papers, 2022–2025 · strength 0.54
  17. Govindarajan Narayanan · 2 shared papers, 2026 · strength 0.54
  18. Chet W. Hammill · 2 shared papers, 2026 · strength 0.54
  19. Norma Alonzo Palma · 2 shared papers, 2025–2026 · strength 0.51
  20. Lisa A. Ford · 2 shared papers, 2025–2026 · strength 0.51
  21. Thomas Charles King · 2 shared papers, 2025–2026 · strength 0.51
  22. Randall E. Brand · 2 shared papers, 2025–2026 · strength 0.51
  23. Erkut Hasan Borazanci · 2 shared papers, 2025–2026 · strength 0.51
  24. David A. Iannitti · 2 shared papers, 2024–2026 · strength 0.47
  25. Melissa Ellen Hogg · 2 shared papers, 2025–2026 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.